| Patient | Jim Thorpe |
|---|---|
| Date of birth | 1888-05-28 |
| Identifiers | MRN HR-ML011-SYN-TD; SSN (made up) 000-11-9036 |
| Document date | 1951-09-21 |
| Author | Nolan Fairbanks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Coronary disease review in cardiac rehabilitation, lipid recheck, and lip surveillance. [S]
Mr. Thorpe returns ten weeks after ezetimibe was added. He has done 18 cardiac rehabilitation sessions and now walks up the hill to the ball field without stopping. He has had no angina and no nitroglycerin since early summer. The back strain from four weeks ago settled within ten days on acetaminophen, and he is back to full sessions. He uses lip balm with sunscreen and a hat every day. He has no new sore on his lips or in his mouth and no lumps in his neck. [S]
| Element | Detail |
|---|---|
| Cardiac rehabilitation | 18 sessions; walks uphill without stopping |
| Angina | None since early summer |
| Back strain | Resolved within ten days |
| Lip | No new sore; no neck lumps |
| System | Result | Finding |
|---|---|---|
| Ears, nose, mouth, and throat | Negative | No lip or mouth sores; no hoarseness |
| Cardiovascular | Negative | No chest tightness, palpitations, or leg swelling |
| Musculoskeletal | Negative | Back pain resolved; no muscle aches |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1951-06-08 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1951-06-08 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1951-06-08 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeated every 5 minutes up to 3 tablets | One tablet under the tongue as needed for chest pain; call 911 if pain persists 5 minutes after the first tablet | Sublingual route | 1951-06-08 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1951-07-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for back pain; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 1951-08-24 to 1951-09-07 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1951-09-21 | Body height | 185 | cm | S |
| 1951-09-21 | Body weight | 91.6 | kg | S |
| 1951-09-21 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 1951-09-21 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1951-09-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1951-09-21 | Heart rate | 60 | /min | S |
| 1951-09-21 | Respiratory rate | 14 | /min | S |
| 1951-09-21 | Body temperature | 36.6 | Cel | S |
| 1951-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1951-09-21 | Cholesterol [Mass/volume] in Serum or Plasma | 118 | mg/dL | <=199 mg/dL | Normal | S |
| 1951-09-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 51 | mg/dL | Below 100 mg/dL in general; secondary-prevention goal below 55 mg/dL | Normal | S |
| 1951-09-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 1951-09-21 | Triglyceride [Mass/volume] in Serum or Plasma | 115 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 1951-09-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/76, pulse 60; weight 91.6 kg |
| Head and neck | Lip scar mature and soft; no nodularity or new lesion; mouth normal; no neck nodes |
| Back | Full, painless range of motion |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Non-healing lesion of the left lower lip for about three months: a 1.2 cm firm, crusted ulcer on the vermilion that bleeds when touched, on a background of dry, scaly lips from years of outdoor work; no numbness of the lip or chin and no palpable neck nodes. Suspicious for squamous cell carcinoma; incisional biopsy taken today and otolaryngology consultation booked | resolved | confirmed | K13.0 | S — Synthetic presenting problem linked to his documented lip cancer; superseded by the biopsy diagnosis. |
| Chronic coronary disease with stable exertional angina: tightness in the chest when walking uphill or carrying loads for about a year, relieved by two or three minutes of rest, never at rest; heart attack eight years ago, treated in hospital, with no regular care or medicines since. Resting ECG: sinus rhythm with Q waves in the inferior leads. Synthetic modern episode linked to his documented heart attacks | active | confirmed | I25.119 | S — Synthetic modern coding of the documented heart disease. |
| Squamous cell carcinoma of the left lower lip (external vermilion): invasive, well-differentiated keratinizing squamous cell carcinoma on incisional biopsy; 1.2 cm, no palpable neck nodes; clinical stage T1 N0 (AJCC 8th edition, lip and oral cavity). Synthetic modern episode linked to his documented lip cancer | active | confirmed | C00.1 | S — Synthetic modern diagnosis; the cited sources do not record the type of his lip cancer. |
| Acute low back strain after lifting bags of infield clay while preparing a ball field: pain across the lower back without leg pain, numbness, weakness, or bladder or bowel change; no red flags apart from a recent, fully excised early lip cancer; resolved | resolved | confirmed | S39.012A | S — Synthetic acute injury; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Examination of the lips, mouth, and neck | Every 1 to 3 months in year 1, 2 to 6 months in year 2, 4 to 8 months in years 3 to 5, then yearly | Completed today | No recurrence or new lesion; no neck nodes |
| Self-management | Sun protection of the lips and skin | Every visit | Completed today | Lip balm with sunscreen and a hat daily |
| Self-management | Tobacco and alcohol use | Every visit | Completed today | Tobacco-free |
| Referral | Dental evaluation | After diagnosis, then routine | Due | Not yet arranged; he is deciding where to go |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 124/76, at goal |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 91.6 kg, BMI 26.8; rehabilitation three times a week |
| Survey | Angina frequency and nitroglycerin use | Every visit | Completed today | None; no nitroglycerin |
| Medication safety | Adherence and side effects: aspirin, high-intensity statin, beta-blocker | Every visit | Completed today | All taken daily, with ezetimibe; no side effects |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months; goal LDL below 55 mg/dL | Completed today | Ten weeks after adding ezetimibe: total cholesterol 118, LDL 51, HDL 44, triglycerides 115 mg/dL; at goal |
| Referral | Cardiac rehabilitation | After a heart attack or for stable angina: up to 36 sessions | Completed today | 18 of 36 sessions |
| Survey | Depression screen (PHQ-2 or PHQ-9) | Yearly | Up to date | PHQ-2 1 at intake; next at the preventive visit |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (cancer of the lip and oral cavity) (2026); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease monograph (2026)
Follow-up: Preventive visit in two weeks. Lip surveillance and coronary disease review in about five weeks. Next scheduled visit 1951-10-05: periodic adult preventive visit. [S]